UroGen Pharma Ltd (NAS:URGN)
$ 13.05 -0.76 (-5.5%) Market Cap: 549.59 Mil Enterprise Value: 437.91 Mil PE Ratio: 0 PB Ratio: 18.74 GF Score: 72/100

Urogen Pharma Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 02:45PM GMT
Release Date Price: $8.35 (-1.65%)
Unidentified Analyst

Good morning, and thank you for joining JPMorgan's Annual Healthcare Conference. My name is Ting Jiang, I'm a health care banker here at JPMorgan.

Before I begin, just want to quickly remind our audience, so please feel free to submit your questions using the blue button on your screen. We will address them during Q&A.

With that, I'm pleased to introduce the session's presenter, Ms. Liz Barrett, President and CEO of UroGen Pharma. Without further ado, I'll let Liz take it away.

Elizabeth A. Barrett
UroGen Pharma Ltd. - President, CEO & Director

Thank you, and thank you, JPMorgan for having us here. This conference, as always, very special to me because 3 years ago, I think it was day 6 of me being in this role that I presented at JPMorgan. And so while I do wish, as I think many of you do, we couldn't be in person, just happy to be here with you. I know that you'll be following along with the presentation. I have it in front of me. So I'll try to remember to tell you which slide I'm on. And I'm again happy to be here.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot